(i) Anti-EGFR-targeted Gd10B6 NPs delivered high amounts of 10B (158 μg/g tumor) and 157Gd (56.8 μg/g tumor) to head and neck tumors in mice, enabling effective combined GdBNCT with long survival times (Shanmugam et al., 2023). This evidence concerns the gene EGFR and neoplasm.